- 07:27 PM Barclays Bk, Calyon Bk move Bombay HC against Wock...
- 07:17 PM Nirmal Bang's after market report
- 07:13 PM Prestige Group to file DRHP soon: Sources
- 07:11 PM Karnataka govt approves Mittal's Rs 30K cr steel p...
- 07:00 PM Supports for rupee around 46.40/46.30: Commtrendz
- 06:49 PM Dubai debt crisis can be resolved locally: MIG Inv...
- 06:44 PM Angel Broking neutral on Tata Steel
- 06:31 PM Mkts overreacting to Dubai crisis: Expert
- 06:11 PM Aegon Religare favours power sector stocks
- 06:11 PM Don't worry about Dubai crisis, buy on dips: Exper...



Broking house, Sharekhan is bullish on Cadila Healthcare and has recommended buy rating on the stock with a target of Rs 425.
Sharekhan report on Cadila Healthcare:
Zydus Cadila (Cadila) has acquired a 97.5% stake in Mumbai-based Liva Healthcare(Liva), a mid-sized Indian pharma company, in an all-cash deal. The all-cashtransaction will be funded through cash accruals and debt. The size of the dealhas not been disclosed.
The acquisition of Liva will enable Cadila to foray into the Rs 1,500-crored ermatology segment in India and thus strengthen its domestic product portfolio,allowing it to offer a more comprehensive product range. With Livaís 325-peoplesales force, which already has established relationships and strong brand equityamongst the dermatologists, cosmetologists and beauticians, Cadila will be ableto make fast in-roads into this rapidly growing segment.
Cadila has received three product approvals from the US Food and Drug Authority(US FDA) in quick succession. The company has received the final approval tomarket Azathioprine tablets of 50mg strength and has received tentative approvalsfor Divalproex Sodium Extended Release tablets in strengths of 250mg and 500mg,and Venlafaxine Hydrochloride tablets in strengths of 25mg, 37.5mg, 50mg, 75mg and 100mg.
We estimate the above three products would together contribute $13.1 million(approximately Rs40.5 crore) in FY2008E and $15.4 million (approximately Rs69crore) in FY2009E to Cadilaís total revenues. The same three products are likelyto contribute approximately Rs0.90 to Cadilaís FY2008E earnings and Rs1.10 toits FY2009E earnings.
At the current market price of Rs326, Cadila is trading at 14.8x its estimatedFY2008 earnings and at 12.2x its estimated FY2009 earnings. The stock hasunderperformed the market in recent times, but we believe that as Cadilaísinternational efforts start translating into gains and growth in the domestic marketrebounds, the stockís performance would improve. Considering the strong growthmomentum of the company, we maintain our Buy recommendation on the stockwith a price target of Rs 425.
Zydus Cadila acquires Liva Healthcare
Cadila has acquired a 97.5% stake in Mumbai-based Liva, a mid-sized, Indianpharma company, in an all-cash deal. The all-cash transaction will be funded throughcash accruals and debt. The size of the deal has not been disclosed.
Valuation & view
The acquisition of Liva will enable Cadila to foray into the Rs1,500-crore dermatology segment in India and thus strengthen its domestic product portfolio, allowing it to offer a more comprehensive product range. With Livaís 325-people sales force, which already has established relationships and strong brand equity amongst the dermatologists, cosmetologists and beauticians, Cadila will be able to make fast in-roads into this rapidly growing segment.
Further, the above three product approvals are expected to strengthen Cadilaís US product portfolio. Cadila has filed 44 abbreviated new drug applications (ANDAs) till date. As these ANDAs get approved by the US FDA, the same would translate into a strong product portfolio. With a target to file 20-25 ANDAs and launch six to seven new products every year, we believe Cadila is set to reap handsome gains from its US business.
At the current market price of Rs326, Cadila is trading at 14.8x its estimated FY2008 earnings and at 12.2x its estimated FY2009 earnings. The stock has underperformed the market in recent times, but we believe that as Cadilaís international efforts start translating into gains and growth in the domestic market rebounds, the stockís performance would improve. At these levels, the stock is available near its 52-week low level. Considering the strong growth momentum of the company, we view this as a strong buying opportunity and hence maintain our Buy recommendation on the stock with a price target of Rs425.
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- Dubai crisis: Which Indian companies may be affected
- 10 companies that MF managers love
- Dubai jitters: Will bears overtake investor confidence now?
- Global mkts panic on Dubai's debt rescheduling
- Indian mkts rattled from Dubai default impact

- Ganeshaspeaks: Market prediction for Nov 27
- Mkts singe in Dubai crisis, end down despite smart recovery
- Ashwani Gujral's top five picks for today's trade

- Nifty slips over 2%, breaches 4900 on Dubai's debt concerns
- China`s 50-year bond
Source: ft.com
- Lanco Infra tying up funds for three power projects
Source: Business Line
- RIL units to get 20% of gas needs from D-6
Source: Business Line
- No need to ban cotton export, says Maran
Source: Business Line










